Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith; Tatiana M. Knox; Ivona Filic; Kara M. Soroko; Benjamin K. Eschle; Margaret K. Wilkens; Prafulla C. Gokhale; Francis Giles; Andrew Griffin; Bill Brown; Geoffrey I. Shapiro; Beth E. Zucconi; Philip A. Cole; Madeleine E. Lemieux; Christopher A. French

doi:10.1158/1535-7163.MCT-20-0087

Small Molecule Therapeutics

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux and Christopher A. French

Chevaun D. Morrison-Smith

1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tatiana M. Knox

1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ivona Filic

1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Ivona Filic

Kara M. Soroko

2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Benjamin K. Eschle

2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Margaret K. Wilkens

2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Prafulla C. Gokhale

2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francis Giles

3Developmental Therapeutics Consortium, Chicago, Ilinois.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Francis Giles

Andrew Griffin

4Praxis Precision Medicines, Cambridge, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bill Brown

5Paraza Pharma Inc., Montreal, Quebec, Canada.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Geoffrey I. Shapiro

6Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Beth E. Zucconi

7Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philip A. Cole

7Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Madeleine E. Lemieux

8Bioinfo, Plantagenet, Ontario, Canada.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Madeleine E. Lemieux

Christopher A. French

1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Christopher A. French
For correspondence: cfrench@bwh.harvard.edu

DOI: 10.1158/1535-7163.MCT-20-0087 Published July 2020

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

July 2020
Volume 19, Issue 7

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Mol Cancer Ther July 1 2020 (19) (7) 1406-1414; DOI: 10.1158/1535-7163.MCT-20-0087

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Mol Cancer Ther July 1 2020 (19) (7) 1406-1414; DOI: 10.1158/1535-7163.MCT-20-0087

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Main menu

User menu

Search

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Purchase access

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Articles

Info for

About MCT